358 related articles for article (PubMed ID: 19401472)
1. Effect of non-ergot dopamine agonists on health-related quality of life of patients with restless legs syndrome.
Talati R; Phung OJ; Mather J; Coleman CI
Ann Pharmacother; 2009 May; 43(5):813-21. PubMed ID: 19401472
[TBL] [Abstract][Full Text] [Related]
2. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies.
Fulda S; Wetter TC
Brain; 2008 Apr; 131(Pt 4):902-17. PubMed ID: 17932100
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of dopamine agonists in restless legs syndrome.
Hornyak M; Trenkwalder C; Kohnen R; Scholz H
Sleep Med; 2012 Mar; 13(3):228-36. PubMed ID: 22281001
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score > or = 24 points--data from the ropinirole clinical trial programme.
Giorgi L; Ritchie SY; Kirsch JM
Curr Med Res Opin; 2006 Oct; 22(10):1867-77. PubMed ID: 17022844
[TBL] [Abstract][Full Text] [Related]
5. What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications.
Hornyak M; Scholz H; Kohnen R; Bengel J; Kassubek J; Trenkwalder C
Sleep Med Rev; 2014 Apr; 18(2):153-64. PubMed ID: 23746768
[TBL] [Abstract][Full Text] [Related]
6. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study.
Walters AS; Ondo WG; Dreykluft T; Grunstein R; Lee D; Sethi K;
Mov Disord; 2004 Dec; 19(12):1414-23. PubMed ID: 15390050
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome.
Quilici S; Abrams KR; Nicolas A; Martin M; Petit C; Lleu PL; Finnern HW
Sleep Med; 2008 Oct; 9(7):715-26. PubMed ID: 18226947
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome.
Bliwise DL; Freeman A; Ingram CD; Rye DB; Chakravorty S; Watts RL
Sleep Med; 2005 Mar; 6(2):141-7. PubMed ID: 15716217
[TBL] [Abstract][Full Text] [Related]
9. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial.
Montplaisir J; Karrasch J; Haan J; Volc D
Mov Disord; 2006 Oct; 21(10):1627-35. PubMed ID: 16874755
[TBL] [Abstract][Full Text] [Related]
10. Predictors of health-related quality of life in sufferers with restless legs syndrome: a multi-national study.
McCrink L; Allen RP; Wolowacz S; Sherrill B; Connolly M; Kirsch J
Sleep Med; 2007 Jan; 8(1):73-83. PubMed ID: 17023208
[TBL] [Abstract][Full Text] [Related]
11. Assessing health-related quality of life in patients with restless legs syndrome.
Happe S; Reese JP; Stiasny-Kolster K; Peglau I; Mayer G; Klotsche J; Giani G; Geraedts M; Trenkwalder C; Dodel R
Sleep Med; 2009 Mar; 10(3):295-305. PubMed ID: 18359664
[TBL] [Abstract][Full Text] [Related]
12. Ropinirole treatment for restless legs syndrome.
Bogan RK
Expert Opin Pharmacother; 2008 Mar; 9(4):611-23. PubMed ID: 18312162
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study--the PRELUDE study.
Partinen M; Hirvonen K; Jama L; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
Sleep Med; 2006 Aug; 7(5):407-17. PubMed ID: 16815748
[TBL] [Abstract][Full Text] [Related]
14. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment of restless legs syndrome with dopamine agonists.
Ondo W; Romanyshyn J; Vuong KD; Lai D
Arch Neurol; 2004 Sep; 61(9):1393-7. PubMed ID: 15364685
[TBL] [Abstract][Full Text] [Related]
16. Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial.
Ferini-Strambi L; Aarskog D; Partinen M; Chaudhuri KR; Sohr M; Verri D; Albrecht S
Sleep Med; 2008 Dec; 9(8):874-81. PubMed ID: 18952497
[TBL] [Abstract][Full Text] [Related]
17. Effect of nonergot dopamine agonists on symptoms of restless legs syndrome.
Baker WL; White CM; Coleman CI
Ann Fam Med; 2008; 6(3):253-62. PubMed ID: 18474889
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study.
Garcia-Borreguero D; Winkelman J; Adams A; Ellis A; Morris M; Lamb J; Layton G; Versavel M;
Sleep Med; 2007 Mar; 8(2):119-27. PubMed ID: 17239657
[TBL] [Abstract][Full Text] [Related]
19. Appropriate use of dopamine agonists and levodopa in restless legs syndrome in an ambulatory care setting.
Molokwu OC
Ann Pharmacother; 2008 May; 42(5):627-32. PubMed ID: 18381842
[TBL] [Abstract][Full Text] [Related]
20. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements.
Manconi M; Ferri R; Zucconi M; Oldani A; Fantini ML; Castronovo V; Ferini-Strambi L
Sleep Med; 2007 Aug; 8(5):491-7. PubMed ID: 17512780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
